Health Canada approves DAKLINZA
This all-oral therapy without interferon and ribavirin was approved today by Health Canada.
Daklinza (daclatasvir) from BMS, is a INS5A inhibitor, for patients with genotype 1,2,3, with or without cirrhosis, in combination with sofosbuvir (Sovaldi), indicated for 12 or 24 weeks regimen.
Perhaps in Quebec next year.